Galectin Offers Subgroup Approach For Struggling NASH Candidate

Having failed to meet its primary endpoint in consecutive Phase II studies, Galectin hopes to move GR-MD-02 forward in NASH in patients with cirrhosis who have not developed esophageal varices.

scientists doing lab research on digital screen

Galectin Therapeutics Inc. thinks subgroup analysis of its failed Phase IIb study in non-alcoholic steatohepatitis (NASH) highlights a way forward for its complex carbohydrate drug GR-MD-02, but investors don't seem to agree.

The Norcross, Ga., biotech reported Dec. 5 that GR-MD-02, targeting the galectin-3 protein which plays a role in fatty liver...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D